Neogenix Oncology to Present Data on Novel Carcinoma Biomarker at AACR’s 2010 Special Conference on Colorectal Cancer

GREAT NECK, N.Y.--(BUSINESS WIRE)-- Neogenix Oncology, Inc. (Neogenix) announced today that it will present data from its new carcinoma biomarker (16C3). The company continues to use its platform to develop a portfolio of cancer markers for detection of cancer in blood and tumor samples. Neogenix has demonstrated the presence of the 16C3 antigen in a broad range of adenocarcinomas and presents its first results with this biomarker from patient serum samples.

This study provides proof of concept utilizing an ELISA platform in patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Association for Cancer Research’s first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.

Neogenix presents both immunohistochemistry (IHC) and serum biomarker data using 16C3, its novel, proprietary monoclonal antibody that specifically targets cancer cells. The prospective study, being conducted at Conemaugh Cancer Center, in Johnstown, PA, provides for the evaluation of blood serum samples from patients confirmed with pancreatic or colon cancer. Preliminary results demonstrate the Neogenix biomarker assay’s ability to differentiate between blood serum of healthy donors and that of patients with colorectal or pancreatic cancer. In addition, the results of the 16C3 biomarker test indicate superior sensitivity as compared to commercially available CEA and CA19-9 assays. A complete data set will be presented at the AACR Meeting.

"We are very excited about the study results and our growing portfolio of cancer markers which hold promise for the early detection of these devastating diseases. The combination of our therapeutic and diagnostic programs could lead to improved outcomes for cancer patients through early diagnosis and intervention,” says Philip M. Arlen, M.D, President and CEO of Neogenix Oncology.

Poster Presentation Information:

Abstract Title: A Novel Antibody That Can Detect a Serum Biomarker: Utility for Detection and Prognosis in Colorectal and Pancreatic Cancer

Poster Session Date/Time: Thursday, October 28, 2010 from 12:30-2:30 p.m.

Session Location: Millennium Hall, Loews Hotel, 2nd Floor

Location: Poster Board A30

The full abstract can be accessed through the AACR website and the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.

About Neogenix Oncology

Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer.

Forward Looking Statements

Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

RMT PR Management
New York, NY
RoseMarie Terenzio, 212-414-1909
c: 917-913-7226
[email protected]

KEYWORDS:   United States  North America  New York  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Research  Science

MEDIA:

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.